›› 2018, Vol. 38 ›› Issue (3): 339-.doi: 10.3969/j.issn.1674-8115.2018.03.018

• Review • Previous Articles     Next Articles

Clinical advances in monoclonal antibody against PCSK9 for coronary atherosclerotic heart disease

LUO Cong-cong1 , BAO Chun-rong2 , HE Bin1   

  1. 1. Department of Anesthesiology and SICU, 2. Department of Cardiothoracic Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2018-03-28 Published:2018-05-03
  • Supported by:
    Natural Science Foundation of China, 81470390; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152218; Biomedical Engineering Cross Research Foundation of Shanghai Jiao Tong University, YG2013MS21

PDF (PC)

973

Abstract: Coronary atherosclerotic heart disease (CHD) remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a major risk factor. Lower levels of LDL-C can effectively reduce the risk of CHD. To date, lipid-lowering medicines such as statins are effective in lowering LDL-C, but a proportion of patients do not achieve lipid reduction target with statins or are intolerant to statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of agents reducing LDL-C which gain more and more concerns. Through inhibitory effect on PCSK9 and increasing low-density lipoprotein receptors recycling, they can significantly reduce serum LDL-C levels. PCSK9 inhibitors are currently in phase Ⅲ of clinical trials, and the results showed that they had good lipid-lowering effects and tolerability. This review provided an overview of the latest advances and challenges about PCSK9 inhibitors.

Key words: proprotein convertase subtilisin/kexin type 9 (PCSK9), inhibitor, monoclonal antibody, low-density lipoprotein-cholesterol (LDL-C), coronary atherosclerotic heart disease (CHD), hyperlipidemia